Clinical Trial Detail

NCT ID NCT02115243
Title Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Duke University
Indications

melanoma

Therapies

Ipilimumab

Age Groups: adult

No variant requirements are available.